UNSPSC 51183405: Mitiglinide calcium

This classification denotes an anti-diabetic agent with the molecular formula 2C19H24NO3.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P5WOR98G68, chemically known as (s)-2-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)butyric acid calcium salt, but more generally known as mitiglinide calcium, which bears US NIH Compound Identifier 5478927. European Medicines Agency schedules mitiglinide calcium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08999MIG.

Most nations, for tariff purposes, schedule mitiglinide calcium under HS 29339990. SMILES: C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].[CA+2].

UNSPSC 51183405 Mitiglinide calcium is a Commodity code representing pharmaceutical products—specifically generic and branded pharmaceuticals including this diabetes medication—that state and local governments procure through cooperative purchasing agreements and direct supply contracts. State and local health departments, correctional facilities, public hospitals, and other government healthcare providers buy under this code to stock formularies and treatment inventories. The issuing-body mix centers on state health and human services departments participating in multistate cooperative purchasing alliances, which aggregate demand across member jurisdictions to achieve volume discounts and standardized supplier relationships.

Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and to certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Evaluation weighted price competitiveness at 75 percent, with secondary factors including fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). The contract term runs two years for new responders with optional extensions, effective July 1, 2026, with awarded products requiring availability in the marketplace by May 15, 2026.